Yarbrough Capital LLC Buys 418 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Yarbrough Capital LLC grew its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 100.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 836 shares of the biotechnology company's stock after purchasing an additional 418 shares during the period. Yarbrough Capital LLC's holdings in Axon Enterprise were worth $440,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Fourth Dimension Wealth LLC purchased a new stake in shares of Axon Enterprise in the fourth quarter worth $30,000. Elequin Capital LP bought a new position in Axon Enterprise in the 4th quarter worth about $46,000. Stonebridge Financial Group LLC purchased a new stake in Axon Enterprise during the 4th quarter valued at about $53,000. CoreFirst Bank & Trust bought a new stake in Axon Enterprise during the 4th quarter valued at about $59,000. Finally, Global Financial Private Client LLC raised its holdings in Axon Enterprise by 11,100.0% in the first quarter. Global Financial Private Client LLC now owns 112 shares of the biotechnology company's stock worth $59,000 after buying an additional 111 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Price Performance

NASDAQ:AXON traded down $3.93 during trading hours on Monday, hitting $787.92. 151,980 shares of the stock traded hands, compared to its average volume of 726,056. The stock has a 50 day moving average price of $643.89 and a 200 day moving average price of $616.38. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The company has a market cap of $61.34 billion, a price-to-earnings ratio of 203.60, a price-to-earnings-growth ratio of 5.17 and a beta of 1.29. Axon Enterprise, Inc. has a 1 year low of $279.02 and a 1 year high of $806.64.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The company had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. During the same period in the previous year, the firm earned $1.15 EPS. The firm's revenue was up 31.3% compared to the same quarter last year. Sell-side analysts forecast that Axon Enterprise, Inc. will post 5.8 EPS for the current fiscal year.

Insider Activity

In other Axon Enterprise news, CRO Cameron Brooks sold 3,000 shares of the company's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $740.76, for a total value of $2,222,280.00. Following the completion of the sale, the executive now directly owns 19,447 shares in the company, valued at approximately $14,405,559.72. This represents a 13.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael Garnreiter sold 87 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $760.00, for a total value of $66,120.00. Following the transaction, the director now owns 24,653 shares in the company, valued at approximately $18,736,280. This represents a 0.35% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,969 shares of company stock valued at $29,909,594. 4.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on AXON. Needham & Company LLC raised their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Barclays lifted their target price on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Northcoast Research downgraded Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. The Goldman Sachs Group boosted their target price on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Finally, Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Axon Enterprise has an average rating of "Moderate Buy" and an average price target of $699.55.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.